We are developing Ambroxol, an oral, repurposed therapy with disease-modifying potential for GBA1-associated Parkinson’s Disease (SidSyn). Originally an over-the-counter mucolytic agent, Ambroxol is now being positioned as the first treatment to target the genetic and molecular drivers of Parkinson’s, not just its symptoms.

Why Ambroxol?

• Targets the Root Cause – Corrects enzyme misfolding in the brain

• Crosses the Blood-Brain Barrier – Acts directly on affected neurons

• Improves Enzyme Function – Reduces toxic protein buildup

• Backed by Clinical Data – Currently in Phase I/II trials